CLTX CAR t presents positive initial phase 1 clinical data

• 75% disease control rate seen at lowest dose level of CLTX CAR T cells • CLTX CAR T was generally well tolerated with no dose limiting toxicities • Persistence of CLTX CAR T cells shown throughout treatment • Results give Chimeric confidence as higher dose levels and dual routes of administration commence • Webinar to be held at 9:30am AEDT today discussing the results.Click here to register. Ch